Search
Cardiol Therapeutics Inc
CRDLAdd to Watchlist
1.050USD
0.0000.00%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
117.47MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
+0.96%
1 Month
-8.70%
6 Months
+5.61%
Year to Date
+10.09%
1 Year
-24.46%
Key Figures
1.050Open
1.090High
412.50KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.37%Turnover Ratio
1.050Prev. Close
1.040Low
267.14KTurnover
LossP/E Static
6.64P/B
0.00%Div Yield TTM
-127.85%ROA
2.33052wk High
1.99Volume Ratio
-36.68MNet Profit
111.87MShares
-0.2786EPS TTM
0.50Beta
-173.96%ROE
1.22552wk Low
4.76%Amplitude
--Gross Margin
117.47MMarket Cap
-1.53Reward/Risk
4.10%Risk Rate
TradingKey Stock Score of Cardiol Therapeutics Inc
Currency: USD Updated: 2026-07-02Key Insights
Cardiol Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 158 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.33.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Cardiol Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Cardiol Therapeutics Inc Highlights
StrengthsRisks
Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Fairly Valued
The company’s latest PE is -3.77, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 25.40M shares, increasing 6.38% quarter-over-quarter.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.25.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
7.333
Target Price
+611.97%
Upside Space
Cardiol Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Cardiol Therapeutics Inc Info
Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.
Ticker SymbolCRDL
CompanyCardiol Therapeutics Inc
CEOElsley (David)
Websitehttps://www.cardiolrx.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
53031.200
+188.700 (+0.36%)
29534.400
+223.000 (+0.76%)
7504.700
+33.200 (+0.44%)
15063.000
+260.000 (+1.76%)
69304.000
+1156.000 (+1.70%)
6381.300
+28.500 (+0.45%)
68.943
+0.599 (+0.88%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4175.460
+53.550 (+1.30%)
FAQs
What is the current price of Cardiol Therapeutics Inc (CRDL)?
The current price of Cardiol Therapeutics Inc (CRDL) is 1.05.
What is the symbol of Cardiol Therapeutics Inc?
The ticker symbol of Cardiol Therapeutics Inc is CRDL.
What is the 52-week high of Cardiol Therapeutics Inc?
The 52-week high of Cardiol Therapeutics Inc is 2.33.
What is the 52-week low of Cardiol Therapeutics Inc?
The 52-week low of Cardiol Therapeutics Inc is 1.23.
What is the market capitalization of Cardiol Therapeutics Inc?
The market capitalization of Cardiol Therapeutics Inc is 117.47M.
Is Cardiol Therapeutics Inc (CRDL) currently rated as Buy, Hold, or Sell?
According to analysts, Cardiol Therapeutics Inc (CRDL) has an overall rating of Buy, with a price target of 7.33.
What is the Earnings Per Share (EPS TTM) of Cardiol Therapeutics Inc (CRDL)?
The Earnings Per Share (EPS TTM) of Cardiol Therapeutics Inc (CRDL) is -0.28.